Triple

T22693775
Position Surface form Disambiguated ID Type / Status
Subject inotersen E561115 entity
Predicate marketedBy P4613 FINISHED
Object Akcea Therapeutics NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Akcea Therapeutics | Statement: [inotersen, marketedBy, Akcea Therapeutics]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Akcea Therapeutics
Context triple: [inotersen, marketedBy, Akcea Therapeutics]
  • A. Akcea Therapeutics chosen
    Akcea Therapeutics is a biopharmaceutical company focused on developing RNA-targeted therapies for rare and serious diseases, particularly in the cardiometabolic and hereditary amyloidosis space.
  • B. Alkermes
    Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
  • C. AbbVie
    AbbVie is a global biopharmaceutical company known for developing and marketing innovative therapies in areas such as immunology, oncology, and neuroscience.
  • D. Regeneron Pharmaceuticals
    Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
  • E. Amgen
    Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454d71b48190a1f80af9f82b6fcf completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1789c6ae481908975b7d27e7624ac completed April 29, 2026, 3:18 a.m.
Created at: April 17, 2026, 3:13 p.m.